HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
Not recruitingISRCTN96439578

Safety study of Dalumin (WS® 1090) in Somatization disorder (ICD 10, F45.0); Undifferentiated somatoform disorder (ICD 10, F45.1); Pain disorder (ICD 10, F45.4); Mental and Behavioural Disorders; Somatization disorder

This study is not recruiting in Germany. It is testing Dalumin (WS® 1090) for Somatization disorder (ICD 10, F45.0); Undifferentiated somatoform disorder (ICD 10, F45.1); Pain disorder (ICD 10, F45.4); Mental and Behavioural Disorders; Somatization disorder.

Somatic symptom disorders, Somatization disorder (ICD 10, F45.0), ...OtherOver 18 Years
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
Not clearly listed
Sponsor
Dr. Willmar Schwabe GmbH & Co. KG (Germany)
Sponsor type
Individual investigator
Study type
Other
Intervention type
Other / unclear
Study phase
Phase IIThis study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Locations
Germany
Age range
Over 18 Years
Official registry ID
ISRCTN96439578
Official title
Multi-center, double-blind, placebo-controlled, randomized phase II study to assess the efficacy, safety and tolerability of Dalumin (WS® 1090) in patients with somatoform disorders

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Loading the security check...
Study ID: ISRCTN96439578. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Not recruiting

Germany

Checked Official study record (opens in a new tab)
Registry details
Registry conditions (original wording)

Somatization disorder (ICD 10, F45.0); Undifferentiated somatoform disorder (ICD 10, F45.1); Pain disorder (ICD 10, F45.4); Mental and Behavioural Disorders; Somatization disorder

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Dr. Willmar Schwabe GmbH & Co. KG (Germany).

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me
Related studies

Explore related studies

Other studies that may be relevant based on condition, country, or study type.